ImmuCell Corporation
ImmuCell Corporation (Nasdaq: ICCC) develops, manufactures and commercializes animal health products intended to improve the health and survivability of newborn dairy and beef calves. Its primary business is the First Defense® line, made from hyperimmunized bovine colostrum and formulated to deliver pathogen-specific… From the company’s description.
Over the twelve months to Jun 30, 2026, ImmuCell Corporation reported revenue of $30.68M, up 8.5% from a year earlier, and net income of $0.79M. Its operating margin was 12.6%, and operations generated $5.89M in cash. In fiscal 2025, it reported revenue of $27.64M, up 4.3% from fiscal 2024, and a net loss of $1.04M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ImmuCell Corporation does
In the company’s own words
ImmuCell Corporation (Nasdaq: ICCC) develops, manufactures and commercializes animal health products intended to improve the health and survivability of newborn dairy and beef calves. Its primary business is the First Defense® line, made from hyperimmunized bovine colostrum and formulated to deliver pathogen-specific antibodies that help prevent calf scours. Products include Dual-Force® and Tri-Shield® single-dose boluses and gels, as well as First Defense Technology® bulk powders for larger calf-rearing operations; the company also sells a California Mastitis Test for on-farm diagnosis. Customers include dairy and beef producers, calf ranches, veterinary clinics and animal health distributors, which distribute products domestically and internationally. First Defense® generated 99% of product sales in 2025. ImmuCell focuses on this product franchise and has paused investment in Re-Tain®, a treatment for subclinical mastitis, while completing studies and exploring licensing or partnership opportunities. The company had 73 employees and manufactured approximately 4.6 million units in 2025. Its website is https://www.immucell.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- PORTLAND, ME
- Fiscal year end
- December
- CIK
- 811641
- SIC
- 2835
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ImmuCell Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ImmuCell Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ImmuCell Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ImmuCell Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ImmuCell Corporation's last four quarterly filings that the numbers alone won't show?”